ICH Q7
Every DSRV article whose Regulatory Snapshot cites ICH Q7: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
- What has FDA cited under ICH Q7?
- 2 DSRV articles cite ICH Q7. Enforcement cases behind them: FDA Warning Letter 320-26-54, CMS Case 722736, to Yangzhou H&R Plastic Daily Chemical Co., Ltd., March 18, 2026; FDA Warning Letter 320-26-55 (case 722497) to Henan Lvyuan Pharmaceutical Co., Ltd., March 26, 2026, made public March 31, 2026, citing cross-contamination risks in multi-product API manufacturing. Inspection exposure across them: 2 high.
- What does DSRV recommend for ICH Q7?
- From the newest article (The Certificate of Analysis Is Not a Test): The diagnostic question is not whether incoming materials are tested but whether the person signing incoming material releases has any organizational reason to approve them regardless of the data; if the QU Director also controls the budget that pays suppliers, the org chart is already a finding. DSRV is decision support, not legal advice; verify against the official source each article names.
- 6 min readHigh exposurecited as a tag
The Certificate of Analysis Is Not a Test
FDA's March 2026 warning letter to Yangzhou H&R Plastic documented three co-occurring failures that define small OTC manufacturer inspection risk: batch release without identity testing, a quality unit with no structural independence, and zero process validation before commercial distribution.
- Case
- FDA Warning Letter 320-26-54, CMS Case 722736, to Yangzhou H&R Plastic Daily Chemical Co., Ltd., March 18, 2026.
- DSRV take
- The diagnostic question is not whether incoming materials are tested but whether the person signing incoming material releases has any organizational reason to approve them regardless of the data; if the QU Director also controls the budget that pays suppliers, the org chart is already a finding.
- 5 min readHigh exposure
Multi-Product API Facilities and the Contamination Gap FDA Finds
FDA's March 2026 warning letter to Henan Lvyuan Pharmaceutical points to a contamination control failure pattern that is structurally embedded in how most multi-product API facilities operate. The gap is not usually in the SOP. It is in the evidence.
- Case
- FDA Warning Letter 320-26-55 (case 722497) to Henan Lvyuan Pharmaceutical Co., Ltd., March 26, 2026, made public March 31, 2026, citing cross-contamination risks in multi-product API manufacturing.
- DSRV take
- FDA's question at a multi-product API site is not whether a cleaning SOP exists but whether the facility can prove, with current product-specific evidence for every equipment-product pair, that its controls are calibrated to the product range it runs today.
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under ICH Q7. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.